Dynamin 1 Peptide Therapy for Tau-Driven Synaptic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Elevated soluble wild-type (WT) tau protein impairs synaptic transmission by over-assembling microtubules and depleting dynamin, leading to vesicle endocytosis and synaptic dysfunction in Alzheimer's disease.
Innovation Solution
A synthetic dodecapeptide corresponding to the dynamin 1 pleckstrin-homology domain is developed to inhibit microtubule-dynamin interaction, preventing tau-induced MT assembly and restoring synaptic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If soluble tau protein levels are elevated, then microtubule assembly is enhanced, but synaptic transmission is impaired due to dynamin depletion
Solution Approach 1:
The patent uses a synthetic peptide (PHDP5) corresponding to the dynamin 1 pleckstrin-homology domain as an intermediary substance. This peptide binds to microtubules and prevents tau-induced microtubule over-assembly, thereby protecting dynamin from depletion while maintaining microtubule stability. The peptide acts as a mediator between tau and dynamin, blocking the harmful interaction without completely disrupting microtubule function.
Solution Approach 2:
The patent changes the concentration and assembly state of microtubules by introducing the PHDP5 peptide. This peptide modulates microtubule dynamics by competing with tau for microtubule binding, thereby controlling the degree of microtubule over-assembly. By adjusting peptide concentration, the system can maintain microtubule stability while preventing pathological over-assembly that leads to dynamin depletion.
2Quantity of substance
If WT tau overexpression occurs, then microtubule density increases, but vesicle endocytosis is impaired
Solution Approach 1:
The PHDP5 peptide serves as an intermediary that selectively interferes with pathological tau-microtubule interactions without disrupting normal microtubule function. By binding to microtubules at specific sites, the peptide prevents excessive tau-induced assembly while allowing dynamin to access and perform endocytosis, thus maintaining vesicle endocytosis efficiency despite increased microtubule density.
3Stability of the object's composition
If dynamin is depleted by tau-induced microtubule assembly, then microtubule stability is enhanced, but synaptic vesicle recycling is impaired
Solution Approach 1:
The PHDP5 peptide acts as a protective intermediary that binds to microtubules and prevents tau from sequestering dynamin. This intermediary mechanism allows microtubules to maintain stability while ensuring dynamin remains available for synaptic vesicle endocytosis and recycling, thus preserving synaptic function despite the presence of elevated tau levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively rescues synaptic transmission by blocking the toxic effects of WT tau, enhancing vesicle endocytosis and maintaining normal synaptic activity.
Implementation Method 1
A synthetic dodecapeptide corresponding to the dynamin 1 pleckstrin-homology domain is developed to inhibit microtubule-dynamin interaction
Implementation Method 2
WT tau newly assembled MTs and strongly impaired synaptic transmission
Implementation Method 3
Capacitance measurements indicated that the primary target of WT h-tau is vesicle endocytosis
Data Source
AI summary
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.